PMC:7441788 / 1191-1822 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T13","span":{"begin":89,"end":97},"obj":"Disease"},{"id":"T14","span":{"begin":184,"end":192},"obj":"Disease"},{"id":"T15","span":{"begin":299,"end":307},"obj":"Disease"},{"id":"T16","span":{"begin":382,"end":390},"obj":"Disease"},{"id":"T17","span":{"begin":537,"end":545},"obj":"Disease"},{"id":"T18","span":{"begin":557,"end":604},"obj":"Disease"},{"id":"T19","span":{"begin":557,"end":590},"obj":"Disease"},{"id":"T20","span":{"begin":606,"end":614},"obj":"Disease"}],"attributes":[{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A15","pred":"mondo_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A16","pred":"mondo_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A17","pred":"mondo_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A18","pred":"mondo_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A19","pred":"mondo_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A20","pred":"mondo_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"e or in combination with a macrolide, did not show any favorable effect on patients with COVID-19. Adverse effects, including prolonged QT interval after taking CQ/HCQ, may develop in COVID-19 patients. Therefore, current data are not sufficient enough to support the use of CQ/HCQ as therapies for COVID-19 and increasing caution should be taken about the application of CQ/HCQ in COVID-19 before conclusive findings are obtained by well-designed, multi-center, randomized, controlled studies.\n\n1. Introduction\nCoronavirus disease-19 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is rapidly sp"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T6","span":{"begin":25,"end":26},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"e or in combination with a macrolide, did not show any favorable effect on patients with COVID-19. Adverse effects, including prolonged QT interval after taking CQ/HCQ, may develop in COVID-19 patients. Therefore, current data are not sufficient enough to support the use of CQ/HCQ as therapies for COVID-19 and increasing caution should be taken about the application of CQ/HCQ in COVID-19 before conclusive findings are obtained by well-designed, multi-center, randomized, controlled studies.\n\n1. Introduction\nCoronavirus disease-19 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is rapidly sp"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T14","span":{"begin":27,"end":36},"obj":"Chemical"},{"id":"T15","span":{"begin":161,"end":163},"obj":"Chemical"},{"id":"T16","span":{"begin":275,"end":277},"obj":"Chemical"},{"id":"T17","span":{"begin":357,"end":368},"obj":"Chemical"},{"id":"T18","span":{"begin":372,"end":374},"obj":"Chemical"}],"attributes":[{"id":"A14","pred":"chebi_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/CHEBI_25106"},{"id":"A15","pred":"chebi_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A16","pred":"chebi_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A17","pred":"chebi_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_33232"},{"id":"A18","pred":"chebi_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"}],"text":"e or in combination with a macrolide, did not show any favorable effect on patients with COVID-19. Adverse effects, including prolonged QT interval after taking CQ/HCQ, may develop in COVID-19 patients. Therefore, current data are not sufficient enough to support the use of CQ/HCQ as therapies for COVID-19 and increasing caution should be taken about the application of CQ/HCQ in COVID-19 before conclusive findings are obtained by well-designed, multi-center, randomized, controlled studies.\n\n1. Introduction\nCoronavirus disease-19 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is rapidly sp"}

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T11","span":{"begin":27,"end":36},"obj":"Chemical"},{"id":"T12","span":{"begin":161,"end":163},"obj":"Chemical"},{"id":"T13","span":{"begin":275,"end":277},"obj":"Chemical"},{"id":"T14","span":{"begin":372,"end":374},"obj":"Chemical"}],"attributes":[{"id":"A11","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_25106"},{"id":"A12","pred":"chebi_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A13","pred":"chebi_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A14","pred":"chebi_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"}],"text":"e or in combination with a macrolide, did not show any favorable effect on patients with COVID-19. Adverse effects, including prolonged QT interval after taking CQ/HCQ, may develop in COVID-19 patients. Therefore, current data are not sufficient enough to support the use of CQ/HCQ as therapies for COVID-19 and increasing caution should be taken about the application of CQ/HCQ in COVID-19 before conclusive findings are obtained by well-designed, multi-center, randomized, controlled studies.\n\n1. Introduction\nCoronavirus disease-19 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is rapidly sp"}

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T11","span":{"begin":89,"end":97},"obj":"Species"},{"id":"T12","span":{"begin":184,"end":192},"obj":"Species"},{"id":"T13","span":{"begin":299,"end":307},"obj":"Species"},{"id":"T14","span":{"begin":382,"end":390},"obj":"Species"},{"id":"T15","span":{"begin":537,"end":545},"obj":"Species"},{"id":"T16","span":{"begin":557,"end":604},"obj":"Species"},{"id":"T17","span":{"begin":606,"end":616},"obj":"Species"}],"attributes":[{"id":"A11","pred":"ncbi_taxonomy_id","subj":"T11","obj":"NCBItxid:2697049"},{"id":"A12","pred":"ncbi_taxonomy_id","subj":"T12","obj":"NCBItxid:2697049"},{"id":"A13","pred":"ncbi_taxonomy_id","subj":"T13","obj":"NCBItxid:2697049"},{"id":"A14","pred":"ncbi_taxonomy_id","subj":"T14","obj":"NCBItxid:2697049"},{"id":"A15","pred":"ncbi_taxonomy_id","subj":"T15","obj":"NCBItxid:2697049"},{"id":"A16","pred":"ncbi_taxonomy_id","subj":"T16","obj":"NCBItxid:2697049"},{"id":"A17","pred":"ncbi_taxonomy_id","subj":"T17","obj":"NCBItxid:2697049"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"e or in combination with a macrolide, did not show any favorable effect on patients with COVID-19. Adverse effects, including prolonged QT interval after taking CQ/HCQ, may develop in COVID-19 patients. Therefore, current data are not sufficient enough to support the use of CQ/HCQ as therapies for COVID-19 and increasing caution should be taken about the application of CQ/HCQ in COVID-19 before conclusive findings are obtained by well-designed, multi-center, randomized, controlled studies.\n\n1. Introduction\nCoronavirus disease-19 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is rapidly sp"}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T15","span":{"begin":99,"end":202},"obj":"Sentence"},{"id":"T16","span":{"begin":203,"end":494},"obj":"Sentence"},{"id":"T17","span":{"begin":496,"end":498},"obj":"Sentence"},{"id":"T18","span":{"begin":500,"end":512},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"e or in combination with a macrolide, did not show any favorable effect on patients with COVID-19. Adverse effects, including prolonged QT interval after taking CQ/HCQ, may develop in COVID-19 patients. Therefore, current data are not sufficient enough to support the use of CQ/HCQ as therapies for COVID-19 and increasing caution should be taken about the application of CQ/HCQ in COVID-19 before conclusive findings are obtained by well-designed, multi-center, randomized, controlled studies.\n\n1. Introduction\nCoronavirus disease-19 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is rapidly sp"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"105","span":{"begin":557,"end":604},"obj":"Species"},{"id":"106","span":{"begin":606,"end":616},"obj":"Species"},{"id":"120","span":{"begin":537,"end":545},"obj":"Disease"},{"id":"46","span":{"begin":75,"end":83},"obj":"Species"},{"id":"47","span":{"begin":193,"end":201},"obj":"Species"},{"id":"56","span":{"begin":27,"end":36},"obj":"Chemical"},{"id":"57","span":{"begin":161,"end":163},"obj":"Chemical"},{"id":"58","span":{"begin":164,"end":167},"obj":"Chemical"},{"id":"59","span":{"begin":275,"end":277},"obj":"Chemical"},{"id":"60","span":{"begin":278,"end":281},"obj":"Chemical"},{"id":"61","span":{"begin":372,"end":374},"obj":"Chemical"},{"id":"62","span":{"begin":375,"end":378},"obj":"Chemical"},{"id":"70","span":{"begin":89,"end":97},"obj":"Disease"},{"id":"71","span":{"begin":184,"end":192},"obj":"Disease"},{"id":"72","span":{"begin":299,"end":307},"obj":"Disease"},{"id":"73","span":{"begin":382,"end":390},"obj":"Disease"}],"attributes":[{"id":"A72","pred":"pubann:denotes","subj":"72","obj":"MESH:C000657245"},{"id":"A73","pred":"pubann:denotes","subj":"73","obj":"MESH:C000657245"},{"id":"A61","pred":"pubann:denotes","subj":"61","obj":"MESH:D002738"},{"id":"A57","pred":"pubann:denotes","subj":"57","obj":"MESH:D002738"},{"id":"A105","pred":"pubann:denotes","subj":"105","obj":"Tax:2697049"},{"id":"A62","pred":"pubann:denotes","subj":"62","obj":"MESH:D006886"},{"id":"A106","pred":"pubann:denotes","subj":"106","obj":"Tax:2697049"},{"id":"A60","pred":"pubann:denotes","subj":"60","obj":"MESH:D006886"},{"id":"A120","pred":"pubann:denotes","subj":"120","obj":"MESH:C000657245"},{"id":"A70","pred":"pubann:denotes","subj":"70","obj":"MESH:C000657245"},{"id":"A46","pred":"pubann:denotes","subj":"46","obj":"Tax:9606"},{"id":"A71","pred":"pubann:denotes","subj":"71","obj":"MESH:C000657245"},{"id":"A58","pred":"pubann:denotes","subj":"58","obj":"MESH:D006886"},{"id":"A47","pred":"pubann:denotes","subj":"47","obj":"Tax:9606"},{"id":"A59","pred":"pubann:denotes","subj":"59","obj":"MESH:D002738"},{"id":"A56","pred":"pubann:denotes","subj":"56","obj":"MESH:D018942"}],"text":"e or in combination with a macrolide, did not show any favorable effect on patients with COVID-19. Adverse effects, including prolonged QT interval after taking CQ/HCQ, may develop in COVID-19 patients. Therefore, current data are not sufficient enough to support the use of CQ/HCQ as therapies for COVID-19 and increasing caution should be taken about the application of CQ/HCQ in COVID-19 before conclusive findings are obtained by well-designed, multi-center, randomized, controlled studies.\n\n1. Introduction\nCoronavirus disease-19 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is rapidly sp"}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T5","span":{"begin":525,"end":532},"obj":"http://purl.obolibrary.org/obo/OGMS_0000031"}],"text":"e or in combination with a macrolide, did not show any favorable effect on patients with COVID-19. Adverse effects, including prolonged QT interval after taking CQ/HCQ, may develop in COVID-19 patients. Therefore, current data are not sufficient enough to support the use of CQ/HCQ as therapies for COVID-19 and increasing caution should be taken about the application of CQ/HCQ in COVID-19 before conclusive findings are obtained by well-designed, multi-center, randomized, controlled studies.\n\n1. Introduction\nCoronavirus disease-19 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is rapidly sp"}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T11","span":{"begin":89,"end":97},"obj":"Disease"},{"id":"T12","span":{"begin":184,"end":192},"obj":"Disease"},{"id":"T13","span":{"begin":299,"end":307},"obj":"Disease"},{"id":"T14","span":{"begin":382,"end":390},"obj":"Disease"},{"id":"T15","span":{"begin":513,"end":535},"obj":"Disease"},{"id":"T16","span":{"begin":537,"end":545},"obj":"Disease"},{"id":"T17","span":{"begin":557,"end":604},"obj":"Disease"},{"id":"T18","span":{"begin":606,"end":616},"obj":"Disease"}],"attributes":[{"id":"A15","pred":"mondo_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A16","pred":"mondo_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A18","pred":"mondo_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A17","pred":"mondo_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"e or in combination with a macrolide, did not show any favorable effect on patients with COVID-19. Adverse effects, including prolonged QT interval after taking CQ/HCQ, may develop in COVID-19 patients. Therefore, current data are not sufficient enough to support the use of CQ/HCQ as therapies for COVID-19 and increasing caution should be taken about the application of CQ/HCQ in COVID-19 before conclusive findings are obtained by well-designed, multi-center, randomized, controlled studies.\n\n1. Introduction\nCoronavirus disease-19 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is rapidly sp"}

{"project":"LitCovid-sample-PD-HP","denotations":[{"id":"T1","span":{"begin":126,"end":147},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0001657"}],"text":"e or in combination with a macrolide, did not show any favorable effect on patients with COVID-19. Adverse effects, including prolonged QT interval after taking CQ/HCQ, may develop in COVID-19 patients. Therefore, current data are not sufficient enough to support the use of CQ/HCQ as therapies for COVID-19 and increasing caution should be taken about the application of CQ/HCQ in COVID-19 before conclusive findings are obtained by well-designed, multi-center, randomized, controlled studies.\n\n1. Introduction\nCoronavirus disease-19 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is rapidly sp"}

{"project":"LitCovid-PubTator","denotations":[{"id":"46","span":{"begin":75,"end":83},"obj":"Species"},{"id":"47","span":{"begin":193,"end":201},"obj":"Species"},{"id":"56","span":{"begin":27,"end":36},"obj":"Chemical"},{"id":"57","span":{"begin":161,"end":163},"obj":"Chemical"},{"id":"58","span":{"begin":164,"end":167},"obj":"Chemical"},{"id":"59","span":{"begin":275,"end":277},"obj":"Chemical"},{"id":"60","span":{"begin":278,"end":281},"obj":"Chemical"},{"id":"61","span":{"begin":372,"end":374},"obj":"Chemical"},{"id":"62","span":{"begin":375,"end":378},"obj":"Chemical"},{"id":"70","span":{"begin":89,"end":97},"obj":"Disease"},{"id":"71","span":{"begin":184,"end":192},"obj":"Disease"},{"id":"72","span":{"begin":299,"end":307},"obj":"Disease"},{"id":"73","span":{"begin":382,"end":390},"obj":"Disease"},{"id":"105","span":{"begin":557,"end":604},"obj":"Species"},{"id":"106","span":{"begin":606,"end":616},"obj":"Species"},{"id":"119","span":{"begin":513,"end":535},"obj":"Disease"},{"id":"120","span":{"begin":537,"end":545},"obj":"Disease"}],"attributes":[{"id":"A46","pred":"tao:has_database_id","subj":"46","obj":"Tax:9606"},{"id":"A47","pred":"tao:has_database_id","subj":"47","obj":"Tax:9606"},{"id":"A56","pred":"tao:has_database_id","subj":"56","obj":"MESH:D018942"},{"id":"A57","pred":"tao:has_database_id","subj":"57","obj":"MESH:D002738"},{"id":"A58","pred":"tao:has_database_id","subj":"58","obj":"MESH:D006886"},{"id":"A59","pred":"tao:has_database_id","subj":"59","obj":"MESH:D002738"},{"id":"A60","pred":"tao:has_database_id","subj":"60","obj":"MESH:D006886"},{"id":"A61","pred":"tao:has_database_id","subj":"61","obj":"MESH:D002738"},{"id":"A62","pred":"tao:has_database_id","subj":"62","obj":"MESH:D006886"},{"id":"A70","pred":"tao:has_database_id","subj":"70","obj":"MESH:C000657245"},{"id":"A71","pred":"tao:has_database_id","subj":"71","obj":"MESH:C000657245"},{"id":"A72","pred":"tao:has_database_id","subj":"72","obj":"MESH:C000657245"},{"id":"A73","pred":"tao:has_database_id","subj":"73","obj":"MESH:C000657245"},{"id":"A105","pred":"tao:has_database_id","subj":"105","obj":"Tax:2697049"},{"id":"A106","pred":"tao:has_database_id","subj":"106","obj":"Tax:2697049"},{"id":"A119","pred":"tao:has_database_id","subj":"119","obj":"MESH:C000657245"},{"id":"A120","pred":"tao:has_database_id","subj":"120","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"e or in combination with a macrolide, did not show any favorable effect on patients with COVID-19. Adverse effects, including prolonged QT interval after taking CQ/HCQ, may develop in COVID-19 patients. Therefore, current data are not sufficient enough to support the use of CQ/HCQ as therapies for COVID-19 and increasing caution should be taken about the application of CQ/HCQ in COVID-19 before conclusive findings are obtained by well-designed, multi-center, randomized, controlled studies.\n\n1. Introduction\nCoronavirus disease-19 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is rapidly sp"}

{"project":"LitCovid-sentences","denotations":[{"id":"T15","span":{"begin":99,"end":202},"obj":"Sentence"},{"id":"T16","span":{"begin":203,"end":494},"obj":"Sentence"},{"id":"T17","span":{"begin":496,"end":498},"obj":"Sentence"},{"id":"T18","span":{"begin":500,"end":512},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"e or in combination with a macrolide, did not show any favorable effect on patients with COVID-19. Adverse effects, including prolonged QT interval after taking CQ/HCQ, may develop in COVID-19 patients. Therefore, current data are not sufficient enough to support the use of CQ/HCQ as therapies for COVID-19 and increasing caution should be taken about the application of CQ/HCQ in COVID-19 before conclusive findings are obtained by well-designed, multi-center, randomized, controlled studies.\n\n1. Introduction\nCoronavirus disease-19 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is rapidly sp"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T1","span":{"begin":126,"end":147},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0001657"}],"text":"e or in combination with a macrolide, did not show any favorable effect on patients with COVID-19. Adverse effects, including prolonged QT interval after taking CQ/HCQ, may develop in COVID-19 patients. Therefore, current data are not sufficient enough to support the use of CQ/HCQ as therapies for COVID-19 and increasing caution should be taken about the application of CQ/HCQ in COVID-19 before conclusive findings are obtained by well-designed, multi-center, randomized, controlled studies.\n\n1. Introduction\nCoronavirus disease-19 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is rapidly sp"}